Just for the record, reporters take no pleasure in questioning the
power of drugs to treat depression. To the contrary: journalism is
notorious for attracting curmudgeons, grumps and depressives—some of my
best friends are one or more of the above—so we wish with all our
hearts that antidepressants would work.
And that scientists wouldn't keep finding evidence that they do not.
In January I reported on the file-drawer effect in studies of antidepressants.
The file-drawer effect refers to the fact that scientifically-sound
studies on the efficacy of antidepressants are not published, as The New England Journal of Medicine article
described. Most of those studies were negative—that is, the drugs did
not help patients much more than a sugar pill (placebo) did, if they
helped at all. That skews the perception of doctors, scientists and you
and me about these drugs; basing our assessment of antidepressants on
published studies alone is like evaluating the prowess of a baseball
team when only its wins and not its losses are reported.
Now a team of scientists has examined many of those unpublished
studies, obtained through a Freedom of Information Act request for the U.S. Food and Drug Administration.
As many people feared, once you include the deep-sixed studies,
antidepressants look hardly more effective than a placebo at lifting
patients’ black cloud of despair.
For their analysis, scientists led by Irving Kirsch of Britain’s
University of Hull started with the data dump they got from the FDA on
fluoxetine (Prozac), venlafaxine (Effexor), nefazodone
(Serzone), and paroxetine (Seroxat /Paxil). They zeroed in on
differences between the improvement reported by patients receiving the
drug and those receiving a placebo. As is standard in such clinical
trials, neither the patients nor the scientists running the study knew
which patients were receiving real drugs and which were receiving
placebos.
In short, there was virtually no difference in the response to drug
vs. placebo of patients who suffered moderate levels of depression, and
a small difference for patients with very severe depression, they
report in the study published this evening in the journal PLoS Medicine. That small difference was, however, clinically insignificant—that is, the difference was so small that government health authorities do not recognize it as a meaningful improvement: on a standard scale of depression,
patients should improve by 3 points, but the spread between placebo and
drug was only 1.8. The difference between drug and placebo was
clinically meaningful only for patients at the upper end of the very
severely depressed category.
The reason for the tiny, or nonexistent, differences? Patients
respond so well to placebo—to the mere thought that something might be
helping them—that there was little room for an actual drug to do more.
Across all groups, response to placebo accounted for more than 80
percent of any improvement. (In contrast, the placebo response to pain
drugs is estimated at about 50 percent.) That suggests that even when
patients are taking and benefiting from, say, Zoloft, the vast majority
of the improvement is due to what their minds are telling them—that is,
the belief that they would be helped. Only the most depressed patients
showed little placebo response.
The scientists conclude that there is little reason to prescribe the
new antidepressants to any but the most severely depressed patients
except as a last resort. Kirsch summarized the findings this way:
“Although patients get better when they take antidepressants, they also
get better when they take a placebo, and the difference in improvement
is not very great. This means that depressed people can improve without
chemical treatments.”
But it seems that there is a larger message here. The placebo
response—the belief that treatment will make you better—is enormously
powerful. Surely it’s time to investigate further how it works and how
it can be harnessed.